Improved outcome of acute myeloid leukaemia in Down's syndrome

Archives of Disease in Childhood

Volumn 81, Issue 1, 1999, Pages 32-37

  Craze, J L ^a,c   Harrison, G ^b   Wheatley, K ^b   Hann, I M ^a   Chessells, J M ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Down's syndrome; Outcome; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL FEATURE; DOWN SYNDROME; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEGAKARYOBLAST; MYELOPOIESIS; NEWBORN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033016392     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.81.1.32     Document Type: Article

References (28)

1. 1 Krivit W, Good RA. Simultaneous occurrence of mongolism and leukaemia. Am J Dis Child 1957;94:289-93.
2. 2 Miller RW. Persons with exceptionally high risk of leukaemia. Cancer Res 1967;27:2420-3.
3. 3 Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome: a review. Pediatr Hematol Oncol 1992;9:139-49.
4. 4 Lie SO, Jonmundsson G, Mellander L, Siimes MA, Yssing M, Gustaffson G, on behalf of the Nordic Society of Paediatric Haematology and Oncology. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Br J Haematol 1996;94:82-8.
5. 5 Creutzig U, Ritter J, Vormoor J, et al. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM study group. Leukemia 1996;10:1677-86.
6. 6 Stiller CA, Eatock EM. Survival from acute non-lymphocytic leukaemia, 1971-88: a population based study. Arch Dis Child 1994;70:219-23.
7. 7 Levitt GA, Stiller CA, Chessells JM. Prognosis of Down's syndrome with acute leukaemia. Arch Dis Child 1990;65: 212-16.
8. 8 Ravindranath Y, Abella E, Krischer JP, et al. Acute myeloid leukaemia in Down's syndrome is highly responsive to chemotherapy: experience on pediatric oncology group AML study 8498. Blood 1992;80:2210-14.
9. 9 Kojima S, Kato K, Matsuyama T, Yoshikawa T, Horibe K. Favorable treatment outcome in children with acute myeloid leukemia and Down syndrome. Blood 1993;81: 3164.
10. 10 Hann IM, Stevens RF, Goldstone AH, et al, on behalf of the Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukaemia. Results of the Medical Research Council's 10th AML trial (MRC AML 10). Blood 1997;89:2311-18.
11. 11 Creutzig U, Ritter J, Zimmermann M, Schellong G, for the AML-BFM Study Group. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukaemia: unexpected results of the childhood acute myelogenous leukemia study BFM-87. J Clin Oncol 1993;11: 279-86.
12. 12 Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977;35:1-39.
13. 13 Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukaemia. Ann Intern Med 1985;103:620-5.
14. 14 Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukaemia of megakaryocytic lineage (M7). Ann Intern Med 1985;103:460-2.
15. 15 Zipursky A, Thorner P, De Harven E, Christensen H, Doyle J. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res 1994;18:163-71.
16. 16 Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: children's cancer group studies 2861 and 2891. Blood 1998;91:608-15.
17. 17 Lie SO. Treatment of acute myeloid leukaemia in children. In: Chessells JM, Hann IM, eds. Bailliere's clinical paediatrics: leukaemia and lymphoma. London: Bailliere Tindall, 1995:757-78.
18. 18 Hayashi Y, Eguchi M, Sugita K, et al. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down's syndrome. Blood 1988;72:15-23.
19. 19 Bain BJ. Transient leukaemia in newborn infants with Down's syndrome [letter]. Leuk Res 1994;18:723-4.
20. 20 Report of a WHO scientific group. Primary immunodeficiency diseases. Clin Exp Immunol 1995;99(suppl 1):1-21.
21. 21 Hurwitz CA, Schell MJ, Pui C-H, Crist WM, Behm F, Mirro J. Adverse prognostic features in 251 children treated for acute myeloid leukemia. Med Pediatr Oncol 1993;21:1-7.
22. 22 Ribeiro RC, Oliveira MSP, Fairclough D, et al. Acute megakaryoblastic leukaemia in children and adolescents: a retrospective analysis of 24 cases. Leuk Lymphoma 1993;10: 299-306.
23. 23 Swansbury GJ, Lawler SD, Alimena G, et al. Long-term survival in acute myelogeneous leukemia: a second follow-up of the fourth international workshop on chromosomes in leukemia. Cancer Genet Cytogenet 1994;73:1-7.
24. 24 Raimondi SC, Kalwinsky DK, Hayashi Y, Behm FG, Mirro J, Williams DL. Cytogenetics of childhood acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1989;40:13-27.
25. 25 Peeters M, Poon A. Down syndrome and leukaemia: unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr 1987;146:416-22.
26. 26 Garre ML, Relling MV, Kalwinsky D, et al. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr 1987; 111:606-12.
27. 27 Taub JW, Matherly LH, Stout ML, Buck SA, Gurney JG, Ravindranath Y. Enhanced metabolism of 1-β-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukaemia. Blood 1996;87:3395-403.
28. 28 Tchernia G, Lejeune F, Boccara J-F, Denavit M-F, Dommergues J-P, Bernaudin F. Erythroblastic and/or megakaryoblastic leukemia in Down syndrome: treatment with low-dose arabinosyl cytosine. J Pediatr Hematol Oncol 1996;18:59-62.